These therapies are poised to reshape treatment standards this year, from next‑gen metabolic drugs to breakthrough advances in oncology, immunology, and rare diseases.
The investment in Valanx Biotech targets site-specific conjugation technology designed to improve uniformity and stability of antibody-drug conjugates.
